Actavis will divest to TPG the pharma business currently known as Aptalis Pharmaceutical Technologies (Pharmatech) a pharmaceutical outsourcing and R&D business within Actavis' subsidiary Aptalis operating in the United States, Canada and Europe. Read the full story

Actavis has entered into an agreement with Mayne Pharma, under which it will divest the U.S. rights to the Doryx Read the full story

AstraZeneca and Actavis have entered into a definitive asset purchase agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of Read the full story

Actavis and Auden Mckenzie have reached a definitive agreement, under which Actavis will acquire Auden Mckenzie for approximately £306 million Read the full story

Merger news: Rumors that Ireland-based Actavis  is still looking to buy up a company or two continue with speculation that it is considering Spanish drugmaker Almirall SA. Actavis, which is domiciled in Ireland, but operates out of Parsippany, N.J. was also earlier rumored to be interested in buying GI drugmaker Salix Pharmaceuticals and Omega Pharma NV. Read the full story

Grunenthal announced the termination of the license agreement with Actavis for the development and commercialization of Cebranopadol Read the full story

Several companies are rumored to be competing to acquire Omega Pharma, the fastest growing consumer healthcare company in the U.K. and Ireland. Read the full story

Actavis and Durata Therapeutics have inked a definitive  agreement to acquire Durata Therapeutics for $675 million. Read the full story

Bloomberg reports, Pfizer is looking at Actavis, the generics maker with a new home address in Ireland, among other targets. Read the full story